| Name | Title | Contact Details |
|---|
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.
CreoDent Prosthetics is a nationally recognized premier full service dental laboratory and a milling center located in New York. With 2 facilities in NYC and Newburgh, NY, CreoDent specialize in both implant and esthetic dentistry. CreoDent continues to grow and develop new products and services to our clients nationwide. Our products and services have given CreoDent its reputation as the finest dental laboratory to work with.
An individualized, trauma-sensitive, and holistic approach to addressing boys` emotional and behavioral issues, and educational, recreational, and vocational goals.
Monell Chemical Senses Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Monell Chemical Senses Center is based in Philadelphia, PA. You can find more information on Monell Chemical Senses Center at www.monell.org